What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 3, 2016, Pages 319-323

  Erro, Roberto ^a,b   Schneider, Susanne A ^a,c   Stamelou, Maria ^d,e,f   Quinn, Niall P ^a   Bhatia, Kailash P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF KIEL   (Germany)

^d UNIVERSITY OF ATHENS   (Greece)

^e HYGEIA HOSPITAL   (Greece)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

CLINICAL FEATURE; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DOPAMINERGIC SYSTEM; DYSTONIA; ESSENTIAL TREMOR; EVIDENCE BASED MEDICINE; HUMAN; MOLECULAR IMAGING; NEUROIMAGING; PARKINSON DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; REVIEW; SCANS WITHOUT EVIDENCE FOR DOPAMINERGIC DEFICIT; DOPAMINERGIC NERVE CELL; FUNCTIONAL NEUROIMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

DIAGNOSTIC ERRORS; DOPAMINERGIC NEURONS; FUNCTIONAL NEUROIMAGING; HUMANS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84964321046     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-310256     Document Type: Review

References (83)

1. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508.
2. Marek K, Jennings DL, Tabamo R, et al. INSPECT: an investigation of the effects of short-term treatment with pramipexole or levodopa on [123I]b-CIT and SPECT imaging in early Parkinson's disease. Neurology 2006;66(Suppl 2):A112.
3. Parkinson Study Group. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007;69:1480-90.
4. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ripinirole verus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101.
5. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-61.
6. Benamer HT, Oertel WH, Patterson J, et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov Disord 2003;18:977-84.
7. Marek K, Jennings D, and Seibyl J. Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa. Neurology 2003;61(6 Suppl 3):S43-8.
8. Bajaj N. SWEDD for the general neurologist. ACNR 2010;10:30-1. http://www.acnr.co.uk/SO10/ACNRSO10-30-SWEDD-article.pdf
9. Soane TA, Grosset D, Lees AJ, et al. Scans without evidence of dopaminergic deficit: diagnosis, etiology, and management. Curr Med Lit 2009;25:93-103.
10. Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 2007;22:2210-15.
11. Schwingenschuh P, Ruge D, Edwards MJ, et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov Disord 2010;25:560-9.
12. Stoessl AJ. Scans without evidence of dopamine deficiency: the triumph of careful clinical assessment. Mov Disord 2010;25:529-30.
13. Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011;95:629-35.
14. Marek K, Seibyl J, Eberly S, et al. Parkinson Study Group PRECEPT Investigators. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 2014;82:1791-7.
15. Marek K, Jennings D, Seibyl J. Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA study. Neurology 2005;64(Suppl 1):A274(Abstract).
16. Batla A, Erro R, Stamelou M, et al. Patients with scans without evidence of dopaminergic deficit: a long-term follow-up study. Mov Disord 2014;29: 1820-5.
17. Bain PG. Dystonic tremor presenting as parkinsonism: long-term follow-up of SWEDDs. Neurology 2009;72:1443-5.
18. Silveira-Moriyama L, Schwingenschuh P, O'Donnell A, et al. Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs). J Neurol Neurosurg Psychiatry 2009;80:744-8.
19. Yang HJ, Kim YE, Yun JY, et al. Comparison of sleep and other non-motor symptoms between SWEDDs patients and de novo Parkinson's disease patients. Parkinsonism Relat Disord 2014;20:1419-22.
20. Sprenger FS, Seppi K, Djamshidian A, et al. Nonmotor symptoms in subjects without evidence of dopaminergic deficits. Mov Disord 2015 Mar 15. doi:10.1002/mds.26204. [Epub ahead of print]
21. Bajaj NP, Wang L, Gontu V, et al. Accuracy of subjective and objective handwriting assessment for differentiating Parkinson's disease from tremulous subjects without evidence of dopaminergic deficits (SWEDDs): an FP-CIT-validated study. J Neurol 2012;259:2335-40.
22. Mian OS, Schneider SA, Schwingenschuh P, et al. Gait in SWEDDs patients: comparison with Parkinson's disease patients and healthy controls. Mov Disord 2011;26:1266-73.
23. Stockner H, Schwingenschuh P, Djamshidian A, et al. Is transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson's disease? Mov Disord 2012;27:1182-5.
24. Cáceres-Redondo MT, Carrillo F, Palomar FJ, et al. DYT-1 gene dystonic tremor presenting as a "scan without evidence of dopaminergic deficit". Mov Disord. 2012;27:1469.
25. Cilia R, Reale C, Castagna A, et al. Novel DYT11 gene mutation in patients without dopaminergic deficit (SWEDD) screened for dystonia. Neurology 2014;83:1155-62.
26. Bajaj NP, Gontu V, Birchall J, et al. Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study. J Neurol Neurosurg Psychiatry 2010;81:1223-8.
27. de Laat KF, van de Warrenburg BP. Re-emergent tremor in a dystonic SWEDD case. Mov Disord 2012;27:462-3.
28. De Rosa A, Carducci C, Carducci C, et al. Screening for dopa-responsive dystonia in patients with scans without evidence of dopaminergic deficiency (SWEDD). J Neurol 2014;261:2204-8.
29. Hall DA, Jennings D, Seibyl J, et al. FMR1 gene expansion and scans without evidence of dopaminergic deficits in parkinsonism patients. Parkinsonism Relat Disord 2010;16:608-11.
30. Ceravolo R, Antonini A, Volterrani D, et al. Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers. Neurology 2005;65:1971-3.
31. Brigo F, Erro R, Marangi A, et al. Differentiating drug-induced parkinsonism from Parkinson's disease: an update on non-motor symptoms and investigations. Parkinsonism Relat Disord 2014;20:808-14.
32. Brigo F, Matinella A, Erro R, et al. [123I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonisms: a meta-analysis. Eur J Neurol 2014;21:1369-1390.
33. Easterford K, Clough P, Kellett M, et al. Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology 2004;62:1435-7.
34. Lorberboym M, Djaldetti R, Melamed E, et al. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med 2004;45:1688-93.
35. Zijlmans JC, Daniel SE, Hughes AJ, et al. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord 2004;19:630-40.
36. Salvati M, Frati A, Ferrari P, et al. Parkinsonian syndrome in a patient with a pterional meningioma: case report and review of the literature. Clin Neurol Neurosurg 2000;102:243-5.
37. Miyagi Y, Morioka T, Otsuka M, et al. Striatal glucose metabolism and [18F] fluorodopa uptake in a patient with tumor-induced hemiparkinsonism. Neurosurgery 1993;32:838-41.
38. Huang CC, Weng YH, Lu CS, et al. Dopamine transporter binding in chronic manganese intoxication. J Neurol 2003;250:1335-9.
39. Gaig C, Marti MJ, Tolosa E, et al. 123I-Ioflupane SPECT in the diagnosis of suspected psychogenic parkinsonism. Mov Disord 2006;21:1994-8.
40. Tolosa E, Coelho M, Gallardo M. DAT imaging in drug induced and psychogenic parkinsonism. Mov Disord 2003;18(Suppl 7):S28-33.
41. Reuter I, Hu MT, Andrews TC, et al. Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome. J Neurol Neurosurg Psychiatry 2000;68:238-41.
42. Jain S, Lo SE, Louis ED. Common misdiagnosis of a common neurological disorder: how are we misdiagnosing essential tremor? Arch Neurol 2006;63:1100-4.
43. Eckert T, Feigin A, Lewis DE, et al. Regional metabolic changes in parkinsonian patients with normal dopaminergic imaging. Mov Disord 2007;22:167-73.
44. Marek K, Seibyl J. Parkinson Study Group. b-CIT scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA-CIT and CALM-CIT Study: long-term imaging assessment. Neurology 2003;60(Suppl 1):A298. (Abstract).
45. Sixel-Döring F, Liepe K, Mollenhauer B, et al. The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases. J Neurol 2011;258:2147-54.
46. Marshall VL, Patterson J, Hadley DM, et al. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun 2006;27:933-7.
47. Menéndez-González M, Tavares F, Zeidan N, et al. Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study. Front Aging Neurosci 2014;6:56.
48. Vlaar AM, Van Kroonenburgh MJ, Kessels AG, et al. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 2007;7:27.
49. Vlaar AM, De Nijs T, Kessels AG, et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol 2008;59:258-66.
50. Serrano Vicente J, Garcia Bernardo L, Duran Barquero C, et al. [Negative predictive value of (123)I Ioflupane SPECT in movement disorders]. Rev Esp Med Nucl 2009;28:2-5.
51. Jang W, Kim JS, Cho JW, et al. Cardiac sympathetic denervation in Parkinson's disease patients with SWEDDs. Neurol Sci 2013;34:1375-82.
52. Stoessl AJ, Halliday GM. DAT-SPECT diagnoses dopamine depletion, but not PD. Mov Disord 2014;29:1705-6.
53. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999;28:99-102.
54. Jennings DL, Seibyl JP, Oakes D, et al. [123I] b-CIT and single photon emission computed tomographic imaging vs clinical evaluation in parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 2004;61:1224-9.
55. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
56. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57:1497-9.
57. Louis ED, Asabere N, Agnew A, et al. Rest tremor in advanced essential tremor: a post-mortem study of nine cases. J Neurol Neurosurg Psychiatry 2011;82:261-5.
58. Fekete R, Li J. Clinical differentiation of essential tremor and Parkinson's disease. Clin Med Insights Case Rep 2013;6:67-74.
59. Utiumi MA, Felício AC, Borges CR, et al. Dopamine transporter imaging in clinically unclear cases of parkinsonism and the importance of scans without evidence of dopaminergic deficit (SWEDDs). Arq Neuropsiquiatr 2012;70:667-73.
60. de Verdal M, Renard D, Collombier L, et al. I123-FP-CIT single-photon emission tomography in patients with long-standing mixed tremor. Eur J Neurol 2013;20:382-8.
61. Erro R, Rubio-Agusti I, Saifee TA, et al. Rest and other types of tremor in adult-onset primary dystonia. J Neurol Neurosurg Psychiatry 2014;85:965-8.
62. Josephs KA, Matsumoto JY, Ahlskog JE. Benign tremulous parkinsonism. Arch Neurol 2006;63:354-7.
63. Selikhova M, Kempster PA, Revesz T, et al. Neuropathological findings in benign tremulous parkinsonism. Mov Disord 2013;28:145-52.
64. Quinn NP, Schneider SA, Schwingenschuh P, et al. Tremor - some controversial aspects. Mov Disord 2011;26:18-23.
65. Clarimon J, Pagonabarraga J, Paisan-Ruiz C, et al. Tremor dominant parkinsonism: clinical description and LRKK2 mutation. Mov Disord 2008;23:518-23.
66. Sommer U, Hummel T, Cormann K, et al. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004;19:1196-202.
67. Marshall VL, Reininger CB, Marquardt M, et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 2009;24:500-8.
68. Ross GW, Petrovitch H, Abbott RD, et al. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol 2004;56:532-9.
69. Bezard E, Dovero S, Prunier C, et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine lesioned macaque model of Parkinson's disease. J Neurosci 2001;21:6853-61.
70. Jennings D, Siderowf A, Stern M, et al. ARS Investigators. Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study. Neurology 2014;83:1739-46.
71. Moccia M, Pappatà S, Picillo M, et al. Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease. J Neurol 2014;261:2112-18.
72. de la Fuente-Fernández R. Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology 2012;78:696-701.
73. Kraemmer J, Kovacs GG, Perju-Dumbrava L, et al. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov Disord 2014;29:1767-73.
74. Morrish P. The meaning of negative DAT SPECT and F-Dopa PET scans in patients with clinical Parkinson's disease. Mov Disord 2005;20:117.
75. McKinley J, O'Connell M, Farrell M, et al. Normal dopamine transporter imaging does not exclude multiple system atrophy. Parkinsonism Relat Disord 2014;20:933-4.
76. O'Sullivan SS, Burn DJ, Holton JL, et al. Normal dopamine transporter single photon-emission CT scan in corticobasal degeneration. Mov Disord 2008;23:2424-6.
77. Kaasinen V, Gardberg M, Röyttä M, et al. Normal dopamine transporter SPECT in neuropathologically confirmed corticobasal degeneration. J Neurol 2013;260:1410-11.
78. Antonini A, Biundo R. Parkinson disease: can dopamine transporter imaging define early PD? Nat Rev Neurol 2014;10:432-3.
79. US FDA. PCNS Advisory Committee Briefing Document. http://www.fda.gov/downloads/AdvisoryCommittees/.../UCM176192.pdf
80. Ottaviani S, Tinazzi M, Pasquin I, et al. Comparative analysis of visual and semi-quantitative assessment of striatal [123I]FP-CIT- SPET binding in Parkinson's disease. Neurol Sci 2006;27:397-401.
81. Darcourt J, Booij J, Tatsch K, et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging 2010;37:443-50.
82. Erro R, Pappatà S, Picillo M, et al. Teaching NeuroImages: pseudo-abnormal DaTscan findings in meningioma-induced parkinsonism. Neurology 2013;80: e147.
83. Janicek AK, Avery RJ, Kuo PH. The pinwheel sign: artifact from head rotation during SPECT acquisition for dopamine transporter imaging. J Nucl Med Technol 2014;42:75-6.